drug_type
RELEVANT_DRUG
intervention_type
Autologous genetically modified T-cell therapy (CAR T)
drug_description
Autologous, lentiviral-transduced T cells expressing an anti-CD20 chimeric antigen receptor (CAR) with CD3ΞΆ and co-stimulatory domains; targets CD20 on B-lineage cells to enable T-cell activation and tumor cell killing.
nci_thesaurus_concept_id
C172063
nci_thesaurus_definition
A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD20 (cluster of differentiation 20), and CD4/CD8 enriched, with potential immunostimulating and antineoplastic activities. Upon administration, MB-CART20.1 specifically recognize and kill CD20-expressing tumor cells. The CD20 antigen, a non-glycosylated cell surface phosphoprotein, is a B-cell specific cell surface antigen expressed in B-cell lineage malignancies and certain melanoma cell subpopulations.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are lentivirally engineered to express an anti-CD20 chimeric antigen receptor with CD3zeta and co-stimulatory domains. Upon binding CD20 on B-lineage cells, CAR signaling activates the T cells, driving proliferation, cytokine release, and targeted cytotoxic killing of CD20-positive tumor cells, resulting in B-cell depletion.
drug_name
MB-CART20.1
nct_id_drug_ref
NCT06508775